• Western blot analysis of lysates from HUVEC and HT-29 cells, using GPR87 Antibody. The lane on the right is blocked with the synthesized peptide.
  • Immunofluorescence analysis of HUVEC cells, using GPR87 Antibody. The picture on the right is blocked with the synthesized peptide.

Anti-GPR87 antibody (221-270 aa) (STJ93399)

SKU:
STJ93399

Current Stock:
Host: Rabbit
Applications: WB/IF/ELISA
Reactivity: Human/Mouse
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-G-protein coupled receptor 87 (221-270 aa) is suitable for use in Western Blot, Immunofluorescence and ELISA research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration: 1 mg/mL
Dilution Range: WB 1:500-1:2000
IF 1:200-1:1000
ELISA 1:5000
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: GPR87
Gene ID: 53836
Uniprot ID: GPR87_HUMAN
Immunogen Region: 221-270 aa
Specificity: GPR87 Polyclonal Antibody detects endogenous levels of GPR87 protein.
Immunogen: The antiserum was produced against synthesized peptide derived from the human GPR87 at the amino acid range 221-270
Function Receptor for lysophosphatidic acid (LPA). Necessary for p53/TP53-dependent survival in response to DNA damage.
Protein Name G-Protein Coupled Receptor 87
G-Protein Coupled Receptor 95
Cellular Localisation Cell Membrane
Multi-Pass Membrane Protein
Alternative Antibody Names Anti-G-Protein Coupled Receptor 87 antibody
Anti-G-Protein Coupled Receptor 95 antibody
Anti-GPR87 antibody
Anti-GPR95 antibody
Anti-FKSG78 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance